Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573959 · ClinicalTrials.gov registry record · NA
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
A NA study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Capso Vision.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT04573959: Completed NA study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Capso Vision.
NCT04573959 is a NA study of Crohn Disease and Inflammatory Bowel Diseases that has completed, run by Capso Vision. The registered enrollment target is 84 participants, below the 204-participant average among 71 other Crohn Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04573959, a NA study of Crohn Disease and Inflammatory Bowel Diseases, has completed, sponsored by Capso Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam® SV-2 and SV-3 capsule endoscopy systems.
Primary Outcome
Images are captured throughout an entire small bowel exam, with complete small bowel exam defined as the ability of the capsule to reach the cecum while still recording images.
Conditions Studied
Interventions
- DEVICE SV-3 Capsule Endoscopy
Study Locations (1)
California
- CapsoVision, Inc. - Saratoga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2020-06-11 |
| Phase | NA |
What the finished NCT04573959 record still lists
NCT04573959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 204-participant average among 71 other Crohn Disease trials with a reported enrollment target (59% lower).
The record links to 5 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which SV-3 Capsule Endoscopy is the first listed.
NCT04573959 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04573959 about?
NCT04573959 is a clinical study titled "Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System". To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam® SV-2 and SV-3 capsule endoscopy systems.
What is the current status of trial NCT04573959?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2015-10-01. Estimated completion is 2020-06-11.
What conditions does trial NCT04573959 study?
This clinical trial studies the following conditions: Crohn Disease, Inflammatory Bowel Diseases, Celiac Disease, Ulcer, Intestinal Disease.
What interventions are being tested in trial NCT04573959?
The interventions under investigation include: SV-3 Capsule Endoscopy (DEVICE).
Who is sponsoring clinical trial NCT04573959?
This trial is sponsored by Capso Vision, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04573959 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04573959's enrollment target sits among peer trials
84 36th of 71 higher than 36 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
RECRUITING · NA
-
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
RISE: A Remote Study of Insomnia Treatment in Crohn's Disease
RECRUITING · NA
-
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI